FULC Earnings Date: Nov 4, 2026 (Estimated) — Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is FULC's next earnings date?
Fulcrum Therapeutics, Inc. (FULC) is expected to report earnings on Wednesday, November 4, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07.
How did FULC do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Fulcrum Therapeutics, Inc. posted EPS of -$0.34 versus the -$0.22 estimate, a miss of 54.5%. Revenue was $0. The stock's 1-day post-earnings move was -3.8%.
How much does FULC stock move after earnings?
FULC beat EPS estimates in 4 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 5.4% (up or down) in the day after earnings.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
🤖 AI Earnings Analysis
FULC trades at $3.75 versus a reported $8.20 average analyst target—about 119% implied upside—but investor-claims investigations add material legal risk.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.22 | -0.34 | -54.55% | $0 | ❌ Miss | -3.76% | +1.34% | +3.49% |
| 2026-04-27 | Q1 2026 | -0.30 | -0.25 | +16.67% | $0 | ✅ Beat | -1.53% | -6.12% | -13.78% |
| 2026-02-24 | Q4 2025 | -0.31 | -0.31 | +0.00% | $0 | ➖ Inline | -21.21% | -28.28% | -38.48% |
| 2025-10-29 | Q3 2025 | -0.29 | -0.31 | -6.90% | $0 | ❌ Miss | -6.40% | -16.30% | +13.20% |
| 2025-07-29 | Q2 2025 | -0.29 | -0.28 | +3.45% | $0 | ✅ Beat | -2.82% | -10.88% | -16.52% |
| 2025-02-25 | Q4 2024 | -0.29 | -0.31 | -6.90% | $0 | ❌ Miss | +0.00% | -12.43% | -15.95% |
| 2024-11-13 | Q3 2024 | -0.41 | -0.32 | +21.95% | $0 | ✅ Beat | -2.20% | -17.31% | +10.71% |
| 2024-07-31 | Q2 2024 | -0.01 | 0.87 | +8800.00% | $80.0M | ✅ Beat | — | — | — |
Showing last 8 quarters.